Non-opioid pain Target customers seeking non-opioid pain relief solutions and alternative therapies, highlighting NeuraLace Medical’s Axon Therapy non-invasive magnetic peripheral nerve stimulation (mPNS) as a differentiator in chronic back pain treatment.

Clinical validation Leverage recent case report and conference exposure at ASPN to pursue early adopter clinics and pain centers, positioning NeuraLace as a credible, evidence-based option for persistent chronic pain cases unresponsive to conventional management.

Strategic partnerships Explore collaborations with medical device distributors, pain management groups, and research institutions to scale adoption, given the company’s startup posture, focus on innovative tech, and partnerships in development.

Growth potential With a revenue range of one to ten million and a small team, position NeuraLace as an agile growth opportunity for investors or partners aiming to accelerate market entry in the chronic pain therapeutics space.

Geographic and market fit Prioritize expansion in the U.S. market from its San Marcos, California base, targeting mid to large pain clinics and hospital systems seeking non-invasive, low-side-effect therapies for chronic pain management.